Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
341 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-10-13)
Due Date
October 13, 2026
Grace Period Ends
April 13, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 13, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Jun 17, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 17, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 17, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jun 17, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 17, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 1, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Apr 24, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Oct 13, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 28, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 28, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 8, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 24, 2020 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Jun 19, 2020 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Jun 15, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 12, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 12, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 10, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Dec 18, 2019 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 18, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Dec 18, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 15, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 22, 2019 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Nov 21, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Nov 17, 2019 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Oct 30, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Oct 29, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 25, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; vaccine preparations; vaccines; biological preparations in the nature of antibodies for use in the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines; diagnostic preparations for medical or veterinary purposes; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; sanitary preparations for medical use; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis
Class 042
Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies
Additional Information
Design Mark
The mark consists of of three arrow points.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042